Adherence-adjusted estimates of benefits and harms from treatment with amoxicillin for LRTI: secondary analysis of a 12-country randomised placebo-controlled trial using randomisation-based efficacy estimators.

ABSTRACT:

Objectives

Estimate the efficacy of amoxicillin for acute uncomplicated lower-respiratory-tract infection (LRTI) in primary care and demonstrate the use of randomisation-based efficacy estimators.

Design

Secondary analysis of a two-arm individually-randomised placebo-controlled trial.

Setting

Primary care practices in 12 European countries.

Participants

Patients aged 18 or older consulting with an acute LRTI in whom pneumonia was not suspected by the clinician.

Interventions

Amoxicillin (two 500 mg tablets three times a day for 7 days) or matched placebo.

Main outcome measures

Clinician-rated symptom severity between days 2-4; new/worsening symptoms and presence of side effects at 4-weeks. Adherence was captured using self-report and tablet counts

SUBMITTER: Gillespie D 

PROVIDER: S-EPMC4360594 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature